Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Prostate Cancer Therapeutics Market Size Shifted, And What Is the Outlook Through 2034?

The market size for prostate cancer treatments has seen significant growth in the past few years. It is forecasted to rise from $11.92 billion in 2024 to $12.88 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. Factors contributing to this expansion in the earlier years include a rise in global prostate cancer cases, elevated consciousness of initial cancer screening and diagnostic procedures, an increase in the elderly male demographic, and a surge in demand for individualized and focused therapies.

The market size of prostate cancer therapeutics is set to witness robust expansion in the upcoming years, reaching a value of $17.77 billion in 2029, marking a compound annual growth rate (CAGR) of 8.4%. The growth during the prediction period is linked to escalating healthcare spending in developing economies, escalating investments in oncology medications, the growing availability of enhanced imaging and diagnostic tools, and increasing preference for minimally invasive and non-surgical treatments. Key trends projected during the forecast period include progress in cancer therapies targeted specifically, incorporation of precision medicine for cancer, advancements in diagnostic imaging tools driven by technology, evolution in radioligand-oriented treatments, and advancements in prostate cancer immunotherapy.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24389&type=smp

What Are the Core Market Drivers Propelling Growth in the Prostate Cancer Therapeutics Industry?

The growth of the prostate cancer therapeutics market is foreseen to be propelled by the rising prevalence of prostate cancer. This is a condition where cancerous cells develop in the tissues of the prostate gland, generally impacting older men. The prevalence is rising due to the aging demographic, as the probability of the disease increases drastically with age, and extended life expectancy results in a larger number of men living long enough to develop it. Therapeutics for prostate cancer aid in disease management by targeting the cancer cells, decelerating the progress, and enhancing the patient’s quality of life with treatments like surgery, radiation, hormone therapy, and newly introduced alternatives like immunotherapy. For example, the National Health Service, a UK government agency, reported in October 2024 that overall cancer diagnoses among men surged by 7% in 2022, escalating from 167,917 to 180,877 cases. This increase was predominantly fueled by a significant uptick in prostate cancer cases, rising by above 25% to 54,732. Hence, the escalating prevalence of prostate cancer is triggering the growth of the prostate cancer therapeutics market.

How Is the Prostate Cancer Therapeutics Market Segmented?

The prostate cancer therapeutics market covered in this report is segmented –

1) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Other Therapies

2) By Drug Class: Androgen Receptor Inhibitors, GnRH Receptor Antagonists, PARP Inhibitors, Immune Checkpoint Inhibitors, Other Drug Classes

3) By Route Of Administration: Oral, Injectable

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Sales

5) By End User: Clinics, Hospitals, Other End Users

Subsegments:

1) By Hormonal Therapy: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, LHRH Antagonists, Anti-Androgens, Androgen Synthesis Inhibitors

2) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Combination Chemotherapy Regimens

3) By Immunotherapy: Sipuleucel-T, Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine-Based Therapies

4) By Targeted Therapy: PARP Inhibitors, Radioligand Therapy, Tyrosine Kinase Inhibitors

5) By Other Therapies: Radiotherapy, Bone-Targeted Therapies, Cryotherapy, High-Intensity Focused Ultrasound

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=24389&type=smp

Which Regions Are Driving the Next Phase of the Prostate Cancer Therapeutics Market Growth?

North America was the largest region in the prostate cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prostate cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theProstate Cancer Therapeutics Market Over the Coming Years?

Key players in the prostate cancer therapeutics sector are prioritizing the development of innovative therapies such as a daily oral pill for progressive prostate cancer. This move aims to enhance patient adherence to their treatment plan and ultimately, improve overall outcomes. These daily treatments are designed to control metastatic castration-resistant prostate cancer by mitigating the impact of testosterone on cancer cells. For instance, in January 2024, Zydus Lifesciences, a company based in India, introduced Rexigo. This is India’s premier once-a-day oral pill containing relugolix for the treatment of advanced prostate cancer. This affordable and comfortable substitute to injectable hormone therapies promptly reduces testosterone levels to control tumor growth while providing superior cardiovascular safety. As an oral therapy, it complicates the need for injectable treatments administered by healthcare professionals, providing improved patient convenience. In India’s context, this introduction marks a significant breakthrough in the management of prostate cancer, giving patients and physicians a new, handy, safe, and cost-effective treatment choice.

View the full report here:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-therapeutics-global-market-report

How Is the Prostate Cancer Therapeutics Market Defined and What Are Its Core Parameters?

Prostate cancer therapeutics refer to the range of medical treatments and interventions used to manage, control, or eliminate prostate cancer, a type of cancer that develops in the prostate gland of men. These therapies aim to slow disease progression, relieve symptoms, improve quality of life, and, in some cases, achieve remission.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24389

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model